QT Imaging Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- QT Imaging reported 3rd quarter 2026 revenue of $7.3 million, up 75% from $4.2 million in the 3rd quarter of 2025, and sold 15 breast acoustic CT scanners compared with 9 a year ago.
- Revenue for the first 9 months of 2026 was $21.3 million compared with $10.7 million in the prior-year period, while scanner sales increased to 43 from 23.
- 3rd quarter gross profit was $3 million, and gross margin was 41.3% compared with 41.2% in the 2nd quarter of 2026.
- Total operating expenses were $5.5 million, including research and development expense of $1.7 million and selling, general, and administrative expense of $3.8 million; operating loss was $2.4 million.
- Net loss was approximately $297,000, or $0.02 per share, compared with a net loss of $4.6 million, or $0.47 per share, in the 3rd quarter of 2025; the 2026 quarter included a $2.4 million noncash gain related to the earnout liability.
- Net cash used in operating activities was $2.2 million in the quarter and $10.7 million for the first 9 months of 2026; cash, cash equivalents, and restricted cash totaled approximately $8.4 million as of September 30th.
- CMS established separate Medicare hospital outpatient payment for diagnostic CT scan examinations effective January 1st, 2027, assigning dedicated CPT billing code 1079P to ambulatory payment classification 5522 with payment status indicator S.
- QT Imaging secured a national group purchasing agreement with Premier through NXE Imaging, providing access to nearly 4,400 hospitals and health systems nationwide.
- Approximately 13,000 women have been imaged using QT Imaging breast acoustic CT technology, and multi-site repeatability reproducibility research showed less than 1% variability in speed of sound measurements under the conditions studied.
- The company received its first commercial order in the Gulf Cooperation Council region from American Hospital Dubai and received regulatory approval in Bahrain and Qatar; it also received regulatory registration in Israel.
- QT Imaging relocated its headquarters and manufacturing operations to an approximately 22,000-square-foot facility in Petaluma, California, which more than doubled available space and approximately doubled scanner manufacturing capacity.
- The company completed its first routine FDA inspection in July with zero Form FDA 483 observations.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, today's event is being recorded. I would now like to turn the conference over to your host, Tirth Patel, with Investor Relations.
Please go ahead. This is Tirth Patel with CORE IR.
Thank you for participating in today's call. Joining me from QT Imaging are Dr. Raluca Dinu, Chief Executive Officer, and Jay Jennings, Chief Financial Officer. I want to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. Any statements that are not statements of historical facts should be deemed to be forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. All forward-looking statements are based on QT Imaging's current beliefs, as well as assumptions made by and information currently available to QT Imaging.
These relate to, among other things, commercialization and manufacturing of the Breast Acoustic CT scanner, the QTI Precision Pathway cloud platform, software development, reimbursement and clinical evidence initiatives, commercial distribution, international shipments, product sales growth, and projected revenue, including the 2026 revenue outlook. For a list and description of the risks and uncertainties associated with the company's business, please see its filings with the Securities and Exchange Commission. Furthermore, the content of this call contains information that is accurate only as of the date of the live broadcast, November 10, 2026. QT Imaging disclaims any obligation, except as required by law, to update or revise any financial or operational projections or other forward-looking statements, whether because of new information, future events, or otherwise. We will also refer to certain non-GAAP measures during the call.
The definitions of these measures and reconciliations to the most directly comparable GAAP measures are available in today's earnings release. I would now like to turn the call over to Dr. Raluca Dinu.
Raluca? Thank you, Tirth. Good afternoon, everyone.
Our third quarter results demonstrate the progress we are making in commercializing our Breast Acoustic CT imaging modality. Revenue was $7.3 million, an increase of 75% year-over-year, and we sold 15 scanners compared to nine a year ago. For the first nine months, revenue reached $21.3 million compared to $10.7 million last year, and the scanner sales increased to 43 from 23. These results reflect meaningful growth. Our next responsibility is to translate that growth into broader clinical adoption. I want to discuss today our execution in four areas. One, U.S. commercialization. Two, clinical adoption and reimbursement. Three, technology and operational scale. Four, international expansion and financial discipline. First, commercial execution. Our U.S. commercial business continued to gain momentum during the third quarter, supported by a stronger direct sales organization, a significantly expanded pipeline of qualified opportunities nationwide, and the receipt of our purchase orders directly from customers across the country.
We strengthened our commercial leadership structure with the three sales leaders now reporting directly to our Chief Commercial Officer, Satrajit Misra. This expanded organization is improving our ability to engage customers, advance opportunities through the sales cycle, and convert growing market interest into purchase orders. These developments represent important progress in building a scalable U.S. commercial operation and expanding our market presence. In parallel, we continue working with our distribution partner, NXC Imaging, a subsidiary of Canon Medical Systems USA, to improve customer placement, strengthen service execution, and drive greater commercial effectiveness.
As we finalize our 2027 commercial structure, we are focused on accelerating sales growth, strengthening customer relationships, and establishing clear accountability across both our direct sales organization and the distribution channel. Looking ahead to 2027, our current domestic distribution agreement with NXC Imaging runs through the end of this year. We are engaged in constructive discussions with NXC and Canon Medical Systems USA regarding our future commercial relationship and scanner with the Precision Pathway SaaS platform purchase commitments. While the new agreement has not yet been finalized, we are encouraged by the progress and see opportunities to strengthen collaboration as we expand into hospitals and imaging centers. An important part of our U.S. commercial strategy is expanding access to large hospital networks and integrating healthcare systems.
We also made significant progress in expanding our access to U.S. hospitals and health systems through Premier, Inc., one of the nation's largest healthcare group purchasing organizations, or GPO. Our Breast Acoustic CT technology was recognized at Premier's Supplier Innovation Celebration following evaluation by a national committee of clinicians and healthcare supply chain experts. Building on this recognition, in October, our distribution partner, NXC Imaging, secured a national group purchasing agreement with Premier, providing access to nearly 4,400 hospitals and health systems nationwide. The agreement establishes pre-negotiated pricing and purchasing terms, simplifying procurement for participating providers. This significantly expands our commercial reach. Our focus now is to convert this access into purchase orders and scanner installations. Second, clinical adoption and reimbursement.
On November 4, just a few days back, we achieved a major reimbursement milestone when the Centers for Medicare & Medicaid Services, or CMS, reversed its earlier proposed non-payment decision and established separate Medicare hospital outpatient payment for diagnostic QTscan examinations effective January 1, 2027. Under the final 2027 Medicare rule, CMS assigned our dedicated CPT billing code 1079T to Ambulatory Payment Classification 5522, with payment status indicator S. Importantly, CMS recognized that physician-ordered QTscan examinations addressing specific diagnostic findings qualify under Medicare's existing diagnostic ultrasound coverage framework. Together with the October 1 implementation of our dedicated CPT billing code, this decision removes the significant reimbursement uncertainty and establishes a clear Medicare hospital outpatient payment pathway for medically necessary diagnostic QTscan examinations. This is a very meaningful commercial milestone for QT Imaging.
Hospitals now have both a dedicated billing code and an established Medicare payment classification, strengthening the business case for adopting our breast imaging technology. Our focus is now on translating this progress into scanner installations and clinical adoption. We have developed a comprehensive coding and billing guide to support hospitals and imaging providers while continuing our engagement with Medicare and commercial payers and expanding the clinical and economic evidence needed for broader coverage. Medicare payment applies to medically necessary physician-ordered diagnostic examinations rather than routine screening. We will continue pursuing additional reimbursement opportunities related to our SaaS platform and AI software improvements. An essential part of our commercial execution is ensuring that imaging centers and hospitals have access to breast radiologists properly trained to interpret the QTscans. We have initiated a structured training program with two established radiology groups under the leadership of Dr. Maryam Ashita.
These relationships will expand our clinical reading capacity and support the adoption of Breast Acoustic CT imaging modality across our growing installed base. Approximately 13,000 women have now been imaged using QT Imaging Breast Acoustic CT technology, making a significant milestone in clinical adoption and reinforcing the growing real-world foundation for advancing quantitative breast imaging. Equally important, our multi-site repeatability reproducibility research demonstrated less than 1% variability in the speed of sound measurements under the conditions studied. This finding support the operator-independent nature of our automated imaging modality, a significant advantage over conventional handheld ultrasound, where image acquisition and measurements are highly dependent on operator technique and experience. Our payer strategy builds on the newly established Medicare reimbursement pathway for medically necessary diagnostic QTscan examinations and focuses on the following clinical applications.
One, diagnostic evaluation of women with dense breasts who require additional imaging following mammography, diagnostic evaluation of high-risk women, particularly those who face barriers to breast MRI. Two, quantitative monitoring of response to neoadjuvant cancer therapy. Three, beyond this application, we see a significant opportunity to improve participation in the breast cancer screening. More than 30% of eligible women are not up to date with recommended screening. Our radiation-free, compression-free technology has the potential to help bring these women back into the standard of care, although routine screening is not currently covered under Medicare. We will work diligently to generate the clinical evidence to pursue the necessary regulatory approvals and expand reimbursement pathway to make QTscan accessible to more women, particularly those who face barriers to conventional breast imaging.
We're aligning our clinical research programs with these priorities, working with our clinical partners to demonstrate QTscan's incremental diagnostic value, potential to reduce unnecessary biopsies, and ability to provide quantitative biomarkers for treatment monitoring. Our objective is to generate the clinical and economic evidence needed to expand payer coverage, strengthen physician adoption, and accelerate broader patient access. Third, technology and operational scale. We're building an integrated breast imaging platform, not simply a manufacturing scanner. Our Breast Acoustic CT technology provides radiation-free, compression-free 3D imaging and quantitative information derived from the acoustic properties of breast tissue. The QTI-Olea Viewer supports clinical interpretation, while QTI Precision Pathway is our cloud platform for image processing and quantitative analysis. We continue to advance our reconstruction software, improve reflection imaging quality, and streamline radiologists' workflows. These investments are designed to strengthen clinical performance and support the scalability of our technology.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
